全文获取类型
收费全文 | 204498篇 |
免费 | 2837篇 |
国内免费 | 158篇 |
专业分类
耳鼻咽喉 | 1374篇 |
儿科学 | 7032篇 |
妇产科学 | 3284篇 |
基础医学 | 20875篇 |
口腔科学 | 2458篇 |
临床医学 | 15106篇 |
内科学 | 37888篇 |
皮肤病学 | 1109篇 |
神经病学 | 19736篇 |
特种医学 | 10639篇 |
外科学 | 32662篇 |
综合类 | 2482篇 |
一般理论 | 11篇 |
预防医学 | 19261篇 |
眼科学 | 3305篇 |
药学 | 11143篇 |
中国医学 | 676篇 |
肿瘤学 | 18452篇 |
出版年
2023年 | 266篇 |
2022年 | 446篇 |
2021年 | 832篇 |
2020年 | 513篇 |
2019年 | 731篇 |
2018年 | 22561篇 |
2017年 | 17869篇 |
2016年 | 20227篇 |
2015年 | 1867篇 |
2014年 | 2016篇 |
2013年 | 2259篇 |
2012年 | 9338篇 |
2011年 | 23297篇 |
2010年 | 20171篇 |
2009年 | 12741篇 |
2008年 | 21507篇 |
2007年 | 23675篇 |
2006年 | 2620篇 |
2005年 | 4113篇 |
2004年 | 5050篇 |
2003年 | 5900篇 |
2002年 | 3953篇 |
2001年 | 530篇 |
2000年 | 607篇 |
1999年 | 446篇 |
1998年 | 505篇 |
1997年 | 424篇 |
1996年 | 252篇 |
1995年 | 250篇 |
1994年 | 219篇 |
1993年 | 148篇 |
1992年 | 108篇 |
1991年 | 156篇 |
1990年 | 173篇 |
1989年 | 140篇 |
1988年 | 97篇 |
1987年 | 79篇 |
1986年 | 66篇 |
1985年 | 67篇 |
1984年 | 50篇 |
1983年 | 56篇 |
1982年 | 62篇 |
1980年 | 70篇 |
1974年 | 44篇 |
1938年 | 86篇 |
1937年 | 56篇 |
1935年 | 57篇 |
1934年 | 52篇 |
1932年 | 58篇 |
1930年 | 52篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
Ramona A. Cole Anita Bansal Debra M. Moriarity William A. Haber William N. Setzer 《Journal of natural medicines》2007,61(4):414-417
The leaf essential oil of Eugenia zuchowskiae from Monteverde, Costa Rica, has been obtained by hydrodistillation and analyzed by GC–MS. The principal constituents of
E. zuchowskiae leaf oil were α-pinene (28.3%), β-caryophyllene (13.2%), α-humulene (13.1%), and α-copaene (8.1%). The leaf essential oil
of E. zuchowskiae showed pronounced in-vitro cytotoxic activity against MCF-7, MDA-MB-468, and UACC-257 human tumor cell lines. The major components
showed cytotoxic activities comparable to doxorubicin (LC50 14–70 μg/ml). 相似文献
73.
A number of cross-over studies on sedation in outpatient oral surgery investigated the quality of sedation produced by intravenous or rectal administration of diazepam. The sedation methods were equally efficient with a mean dose of 0.24 mg/kg (range 0.1–0.4) for i.v. administration and 0.53 mg/kg (range 0.5–0.6) for rectal administration. Eighty-five percent of the patients preferred surgery under sedation and local anaesthesia to local anaesthesia alone. The patients preferred the session in which they experienced stronger sedation, regardless of the route of administration. 相似文献
74.
Katalin Vehmeyer Tibor Hajto Katarina Hostanska Stefan Knemann Holger Lser Reinhard Saller Bernhard Wrmann 《European journal of haematology》1998,60(1):16-20
Abstract: The galactoside-specific plant lectin, Viscum album agglutinin (VAA-I) increases cellular parameters of natural host defence. It also binds to a variety of haematopoietic cells, including progenitors. We investigated whether VAA-I has a stimulatory effect on haematopoietic progenitor cells. Peripheral blood progenitor cells from 7 healthy volunteers were cultured in a colony assay with VAA-I plus erythropoietin (EPO) and stem cell factor (SCF). At 50 pg/ml VAA-I induced a significant increase in the cytokine-dependent clonogenic growth (52% in median, p<0.05). In another set of experiments purified CD34+ cells were isolated from the bone marrow aspirate of 4 patients with non-metastatic breast cancer using fluorescence-activated cell sorting. Binding to CD34+ cells was demonstrated by using directly fluorescence-conjugated VAA-I. Co-incubation with d -galactose significantly abrogated this effect. CD34+ cells were cultured in the presence of EPO, SCF, interleukin-3, granulocyte/monocyte colony-stimulating factor and granulocyte colony-stimulating factor. VAA-I alone had no measurable effect on the clonogenic growth of the isolated cells. However, at concentrations of 100 and 250 pg/ml VAA-I increased the cytokine-dependent proliferation and differentiation of CD34+ cells by a median of 75 and 85%, respectively. The results show that VAA-I binds to haematopoietic progenitor cells and has a co-stimulatory effect on their proliferation. 相似文献
75.
76.
77.
G. Vacca E. Marano V. Brescia Morra R. Lanzillo M. De Vito E. Parente G. Orefice 《Neurological sciences》2007,28(3):133-135
The prevalence of primary headache (PH) in a multiple sclerosis (MS) sample vs. control healthy subjects was investigated at a neurological clinic in 2004–2005: 122 of 238 (51%) MS patients and 57 of
238 (23%) controls proved to be affected by headache. The groups did not differ for the rates of PH types. Headache types
of MS patients were comparable to those of PH patients that were observed at the same institute in a case-control comparison.
First symptoms of headache preceded those of MS in two thirds of cases. Headache features did not significantly change after
MS onset. Comorbidity of MS and PH could be explained by some common clinical and biological traits. 相似文献
78.
Volker Heinemann 《Breast cancer research and treatment》2003,81(1):43-48
Single-agent chemotherapy of metastatic breast cancer is the treatment of choice in patients with slow tumor progression and asymptomatic disease. In this patient group, the choice of drugs is based more on good tolerability than on efficacy. By contrast, symptomatic or rapidly progressing disease requires the use of highly active regimens where more weight is put on reliable antitumor activity. While anthraycline-based combination regimens have set the standard of effective treatment, the addition of docetaxel (and to a lesser extent paclitaxel) has improved tumor response, but failed to induce a consistent prolongation of survival. Based on retrospective analyses, it is hypothesised that the combined use of anthracyclines and taxanes in first-line therapy may be most beneficial in defined subgroups: after adjuvant chemotherapy, in patients with HER-2 gene amplification, possibly also in patients with rapidly progressing visceral disease. 相似文献
79.
80.
Andrea von Berg Renate Engelstätter Predrag Minic Miodrag Sréckovic Maria Luz Garcia Garcia Tadeusz Lato Jan H. Vermeulen Stefan Leichtl Stefan Hellbardt Thomas D. Bethke 《Pediatric allergy and immunology》2007,18(5):391-400
Ciclesonide is an onsite-activated inhaled corticosteroid (ICS) for the treatment of asthma. This study compared the efficacy, safety and effect on quality of life (QOL) of ciclesonide 160 microg (ex-actuator; nominal dose 200 microg) vs. budesonide 400 microg (nominal dose) in children with asthma. Six hundred and twenty-one children (aged 6-11 yr) with asthma were randomized to receive ciclesonide 160 microg (ex-actuator) once daily (via hydrofluoroalkane metered-dose inhaler and AeroChamber Plus spacer) or budesonide 400 microg once daily (via Turbohaler) both given in the evening for 12 wk. The primary efficacy end-point was change in forced expiratory volume in 1 s (FEV1). Additional measurements included change in daily peak expiratory flow (PEF), change in asthma symptom score sum, change in use of rescue medication, paediatric and caregiver asthma QOL questionnaire [PAQLQ(S) and PACQLQ, respectively] scores, change in body height assessed by stadiometry, change in 24-h urinary cortisol adjusted for creatinine and adverse events. Both ciclesonide and budesonide increased FEV1, morning PEF and PAQLQ(S) and PACQLQ scores, and improved asthma symptom score sums and the need for rescue medication after 12 wk vs. baseline. The non-inferiority of ciclesonide vs. budesonide was demonstrated for the change in FEV1 (95% confidence interval: -75, 10 ml, p = 0.0009, one-sided non-inferiority, per-protocol). In addition, ciclesonide and budesonide showed similar efficacy in improving asthma symptoms, morning PEF, use of rescue medication and QOL. Ciclesonide was superior to budesonide with regard to increases in body height (p = 0.003, two-sided). The effect on the hypothalamic-pituitary-adrenal axis was significantly different in favor of ciclesonide treatment (p < 0.001, one-sided). Both ciclesonide and budesonide were well tolerated. Ciclesonide 160 microg once daily and budesonide 400 microg once daily were effective in children with asthma. In addition, in children treated with ciclesonide there was significantly less reduction in body height and suppression of 24-h urinary cortisol excretion compared with children treated with budesonide after 12 wk. 相似文献